Alzheimer's - Dementia, Author Interviews, Brain Injury, Medical Imaging, UCSF / 06.01.2020
Tau Pet Scanning In a Former NFL Play with CTE
MedicalResearch.com Interview with:
[caption id="attachment_52640" align="alignleft" width="180"]
Dr. Mantyh[/caption]
William G. Mantyh, MD
Clinical Fellow, UCSF Memory and Aging Center
Weill Institute for Neurosciences
UCSF
MedicalResearch.com: What is the background for this study?
Response: Similar to Alzheimer’s disease (AD) and other dementing illnesses, Chronic Traumatic Encephalopathy (CTE) is a progressive neurodegenerative condition associated with abnormally folded tau protein in the brain. CTE is thought to be caused by exposure to repetitive head trauma, and recently has been the subject of intense media coverage given the frequency of CTE found in brains of deceased former American professional football players. CTE is almost impossible to confidently diagnose during life as the symptoms are diverse and vary from patient-to-patient. Symptoms can include impairments in memory, multi-tasking, behavioral/mood regulation, and movement. As there are no blood, imaging, or other tests for this disease, one active area of research is developing a test to help doctors diagnose this condition.
As tau tangles in CTE are similar in many respects to those in Alzheimer’s disease, there was hope that PET tracers that detect tau in AD might also work in CTE. Flortaucipir (FTP) is probably the most widely used tau tracer in AD. Recent work has reported some signal from FTP-PET in symptomatic former NFL players and other patients at risk for CTE (Stern et al. New Engl Jour Med 2019; Lesman-Segev et al. Neuroimage Clinical 2019). The overall signal was lower than that observed in Alzheimer’s disease, and, in lieu of correlations with post-mortem findings, it was unclear how well FTP binds to tau pathology in CTE.
Dr. Mantyh[/caption]
William G. Mantyh, MD
Clinical Fellow, UCSF Memory and Aging Center
Weill Institute for Neurosciences
UCSF
MedicalResearch.com: What is the background for this study?
Response: Similar to Alzheimer’s disease (AD) and other dementing illnesses, Chronic Traumatic Encephalopathy (CTE) is a progressive neurodegenerative condition associated with abnormally folded tau protein in the brain. CTE is thought to be caused by exposure to repetitive head trauma, and recently has been the subject of intense media coverage given the frequency of CTE found in brains of deceased former American professional football players. CTE is almost impossible to confidently diagnose during life as the symptoms are diverse and vary from patient-to-patient. Symptoms can include impairments in memory, multi-tasking, behavioral/mood regulation, and movement. As there are no blood, imaging, or other tests for this disease, one active area of research is developing a test to help doctors diagnose this condition.
As tau tangles in CTE are similar in many respects to those in Alzheimer’s disease, there was hope that PET tracers that detect tau in AD might also work in CTE. Flortaucipir (FTP) is probably the most widely used tau tracer in AD. Recent work has reported some signal from FTP-PET in symptomatic former NFL players and other patients at risk for CTE (Stern et al. New Engl Jour Med 2019; Lesman-Segev et al. Neuroimage Clinical 2019). The overall signal was lower than that observed in Alzheimer’s disease, and, in lieu of correlations with post-mortem findings, it was unclear how well FTP binds to tau pathology in CTE.
Dr. Cohen[/caption]
Pieter A. Cohen, MD
Department of Medicine, Cambridge Health Alliance
Somerville, Massachusetts
Harvard Medical School
Boston, Massachusetts
MedicalResearch.com: What is the background for this study?
Response: There has been increasing interest in the use of over-the-counter supplements to help improve memory and cognitive function. However, prior
Dr. Emily Parker Hyle[/caption]
Emily Parker Hyle, M.D.
Assistant Professor of Medicine
Massachusetts General Hospital
MedicalResearch.com: What is the background for this study?
Response: We found that many children who were planning to travel internationally were eligible for MMR vaccination prior to departure but often did not receive it - especially if they were aged 6 months to 6 years. That is because most children do not routinely receive their first dose of MMR till 12-15 months of age and their second dose of MMR till 4-6 years of age. However, ACIP recommendations are different for children who are traveling internationally. The risk of being infected with measles is much higher outside of the US, so it is recommended that children older than 1 year have had 2 MMR vaccinations and that children 6-12 months receive 1 MMR vaccination prior to travel. MMR vaccination is a safe and effective way to greatly reduce the risk of measles infection.
Dr. Perumalswami[/caption]
Chithra R. Perumalswami, MD, MSc
Research Fellow
Center for Bioethics & Social Sciences in Medicine
University of Michigan
[caption id="attachment_51839" align="alignleft" width="133"]
